Two Sigma Investments LP Has $11.23 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Two Sigma Investments LP lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,660,509 shares of the company's stock after purchasing an additional 63,211 shares during the period. Two Sigma Investments LP owned 0.42% of Recursion Pharmaceuticals worth $11,225,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of RXRX. Vanguard Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after buying an additional 9,737,196 shares during the last quarter. Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals during the fourth quarter valued at approximately $99,152,000. Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Geode Capital Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after buying an additional 655,238 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $23,429,000. 89.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RXRX has been the topic of several recent analyst reports. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded up $0.01 during midday trading on Wednesday, hitting $4.40. The company had a trading volume of 22,847,913 shares, compared to its average volume of 13,509,756. The firm has a fifty day simple moving average of $5.04 and a two-hundred day simple moving average of $6.47. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -2.88 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned ($0.39) earnings per share. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.